JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Name: JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Published: 2024
License: Public Domain

Institute of Hematology & Blood Diseases Hospital, China · 2024

ClinicalTrials.gov · Datasets · License: Public Domain · 2024

Open Source ↗

lymphoma t-cell

lymphoma, t-cell, nk-lgl leukemia, t-lgl leukemia, cutaneous t cell lymphoma, cutaneous t cell lymphoma (ctcl), large granular lymphocyte leukemia, large granular lymphocytic leukemia, indolent t-cell lymphoproliferative disorder of the gastrointestinal tract, primary cutaneous acral cd8-positive t-cell lymphoma, mycosis fungoides, indolent t/nk-cell lymphomas, jak1 inhibitor

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 874219
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.